Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

71.80 -0.10 (-0.14%)

Streaming Delayed Price Updated: 11:38 AM EDT, Mar 16, 2026 Add to My Watchlist

Price and Volume

Volume	163,628
Open	72.01
Bid (Size)	71.66 (100)
Ask (Size)	72.00 (100)
Prev. Close	71.90
Today's Range	71.21 - 73.44
52wk Range	26.20 - 84.56
Shares Outstanding	56,367,802
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

VR Adviser Adds Over 1 Million Savara Shares ↗

March 15, 2026

This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.

Via The Motley Fool

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗

March 04, 2026

Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.

Via The Motley Fool

Performance

YTD	-5.3%	-5.3%
1 Month	+5.9%	+5.9%
3 Month	-6.5%	-6.5%
6 Month	+94.8%	+94.8%
1 Year	+77.9%	+77.9%

More News

Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗

March 04, 2026

Via The Motley Fool

Apogee Therapeutics (NASDAQ:APGE) Reports Q4 2025 Results, Highlights Cash Runway and Key 2026 Clinical Catalysts ↗

March 02, 2026

Via Chartmill

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results

March 02, 2026

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗

February 25, 2026

Via The Motley Fool

This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗

February 25, 2026

Via The Motley Fool

Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗

February 25, 2026

Via The Motley Fool

The Great Rotation: Small-Cap Stocks Slay the Giants as Market Breadth Hits Record Highs

February 24, 2026

Via MarketMinute

Apogee Therapeutics to Participate in Upcoming March Conferences

February 24, 2026

From Apogee Therapeutics

Via GlobeNewswire

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗

February 22, 2026

Via The Motley Fool

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗

February 22, 2026

Via The Motley Fool

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗

February 22, 2026

Via The Motley Fool

Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗

February 14, 2026

Via The Motley Fool

Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗

February 14, 2026

Via The Motley Fool

Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026

February 05, 2026

From Apogee Therapeutics

Via GlobeNewswire

The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership

January 26, 2026

Via MarketMinute

What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally ↗

January 11, 2026

Via The Motley Fool

Apogee Therapeutics Chief Medical Officer Sells $817,500 Worth of Shares After Monster December Rally ↗

January 07, 2026

Via The Motley Fool

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

January 06, 2026

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026

January 05, 2026

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

November 10, 2025

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

November 10, 2025

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics to Participate in Upcoming Conferences

November 03, 2025

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million

October 10, 2025

From Apogee Therapeutics

Via GlobeNewswire

Frequently Asked Questions

Is Apogee Therapeutics, Inc. - Common Stock publicly traded?

Yes, Apogee Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Apogee Therapeutics, Inc. - Common Stock trade on?

Apogee Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Apogee Therapeutics, Inc. - Common Stock?

The ticker symbol for Apogee Therapeutics, Inc. - Common Stock is APGE on the Nasdaq Stock Market

What is the current price of Apogee Therapeutics, Inc. - Common Stock?

The current price of Apogee Therapeutics, Inc. - Common Stock is 71.80

When was Apogee Therapeutics, Inc. - Common Stock last traded?

The last trade of Apogee Therapeutics, Inc. - Common Stock was at 03/16/26 11:38 AM ET

What is the market capitalization of Apogee Therapeutics, Inc. - Common Stock?

The market capitalization of Apogee Therapeutics, Inc. - Common Stock is 4.05B

How many shares of Apogee Therapeutics, Inc. - Common Stock are outstanding?

Apogee Therapeutics, Inc. - Common Stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.